ProCE Banner Activity

ALCANZA: Brentuximab Vedotin vs Methotrexate or Bexarotene in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Slideset Download
Conference Coverage
Brentuximab vedotin provided durable objective response and significantly improved CR rates and PFS in patients with CD30+ CTCL.

Released: December 06, 2016

Expiration: December 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen